Abstract
We describe the expression of the extracellular domain of the human α1 nicotinic acetylcholine receptor (nAChR) in lepidopteran insect cells (i-α1-ECD) and its suitability for use in antigen-specific therapies for Myasthenia Gravis (MG). Compared to the previously expressed protein in P. pastoris (y-α1-ECD), i-α1-ECD had a 2-fold increased expression yield, bound anti-nAChR monoclonal antibodies and autoantibodies from MG patients two to several-fold more efficiently and resulted in a secondary structure closer to that of the crystal structure of mouse α1-ECD. Our results indicate that i-α1-ECD is an improved protein for use in antigen-specific MG therapeutic strategies. © 2013 Niarchos et al.
Cite
CITATION STYLE
Niarchos, A., Zouridakis, M., Douris, V., Georgostathi, A., Kalamida, D., Sotiriadis, A., … Tzartos, S. J. (2013). Expression of a highly antigenic and native-like folded extracellular domain of the human α1 subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for myasthenia gravis. PLoS ONE, 8(12). https://doi.org/10.1371/journal.pone.0084791
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.